Drugs that calm overactive T cells by blocking Exportin‑1
Selective Inhibitors of T Cell Activation Target Exportin-1 at Cys528 to Suppress Pathological T Cell Activation
New drugs aim to calm overactive T cells in people with autoimmune diseases or transplant‑related immune problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11249233 on NIH RePORTER |
What this research studies
Researchers are developing drugs that block a protein called Exportin‑1 (XPO1) at a specific site (Cys528) to prevent T cells from becoming pathologically active. They built on earlier small molecules (SITCAs) that calm T cells without broadly suppressing other immune cells and are now defining how these molecules bind their target and improving their properties. The team uses lab studies with human cells and animal models to test how the compounds work, how safe they are, and whether they specifically affect T cells. The goal is to create drug candidates that could eventually be tested in people with autoimmune or transplant‑related immune problems.
Who could benefit from this research
Good fit: People with diseases driven by pathological T cell activation—such as rheumatoid arthritis, graft‑versus‑host disease, transplant rejection, or certain forms of lung fibrosis—would be the likely candidates for future trials.
Not a fit: People whose conditions are not driven by T cell‑mediated inflammation (for example primarily B‑cell disorders, metabolic conditions, or unrelated infections) would likely not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could offer more targeted immune control with fewer side effects than current broad immunosuppressive drugs.
How similar studies have performed: Related drugs that block XPO1 (for example selinexor) are approved for cancer, showing XPO1 is a druggable target, but applying selective inhibition at Cys528 to specifically calm T cells is a newer, less tested approach.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Adams, Drew James — Case Western Reserve University
- Study coordinator: Adams, Drew James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.